Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Common Equity (2024 - 2025)

Historic Common Equity for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $8.0 million.

  • Pharming's Common Equity rose 261.94% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 261.94%. This contributed to the annual value of $7.8 million for FY2024, which is 130.4% up from last year.
  • Per Pharming's latest filing, its Common Equity stood at $8.0 million for Q3 2025, which was up 261.94% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, Pharming's Common Equity ranged from a high of $215.3 million in Q1 2025 and a low of $7195.0 during Q1 2021
  • Over the past 5 years, Pharming's median Common Equity value was $7.5 million (recorded in 2023), while the average stood at $17.3 million.
  • The largest annual percentage gain for Pharming's Common Equity in the last 5 years was 10369430.16% (2022), contrasted with its biggest fall of 9989.69% (2022).
  • Pharming's Common Equity (Quarter) stood at $7350.0 in 2021, then skyrocketed by 102063.07% to $7.5 million in 2022, then increased by 2.13% to $7.7 million in 2023, then increased by 1.3% to $7.8 million in 2024, then rose by 2.37% to $8.0 million in 2025.
  • Its Common Equity stands at $8.0 million for Q3 2025, versus $7.8 million for Q2 2025 and $215.3 million for Q1 2025.